Next Article in Journal
The Role of ATG16 in Autophagy and The Ubiquitin Proteasome System
Next Article in Special Issue
Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients
Previous Article in Journal
Role of Autophagy in Proteostasis: Friend and Foe in Cardiac Diseases
Article Menu

Export Article

Open AccessReview

Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?

1
Department of Neuroscience, Central Clinical School, Monash University, Prahran, VIC 3004, Australia
2
B’ Department of Neurology, Laboratory of Experimental Neurology and Neuroimmunology, AHEPA University Hospital, Stilponos Kiriakides str. 1, 54636 Thessaloniki, Macedonia, Greece
*
Author to whom correspondence should be addressed.
Received: 23 November 2018 / Revised: 12 December 2018 / Accepted: 18 December 2018 / Published: 20 December 2018
(This article belongs to the Special Issue The Molecular and Cellular Basis for Multiple Sclerosis)
Full-Text   |   PDF [2575 KB, uploaded 20 December 2018]   |  
  |   Review Reports

Abstract

The current landscape of therapeutics designed to treat multiple sclerosis (MS) and its pathological sequelae is saturated with drugs that modify disease course and limit relapse rates. While these small molecules and biologicals are producing profound benefits to patients with reductions in annualized relapse rates, the repair or reversal of demyelinated lesions with or without axonal damage, remains the principle unmet need for progressive forms of the disease. Targeting the extracellular pathological milieu and the signaling mechanisms that drive neurodegeneration are potential means to achieve neuroprotection and/or repair in the central nervous system of progressive MS patients. The Nogo-A receptor-dependent signaling mechanism has raised considerable interest in neurological disease paradigms since it can promulgate axonal transport deficits, further demyelination, and extant axonal dystrophy, thereby limiting remyelination. If specific therapeutic regimes could be devised to directly clear the Nogo-A-enriched myelin debris in an expedited manner, it may provide the necessary CNS environment for neurorepair to become a clinical reality. The current review outlines novel means to achieve neurorepair with biologicals that may be directed to sites of active demyelination. View Full-Text
Keywords: Nogo-A; Nogo receptor; multiple sclerosis; axonal dystrophy; inflammatory demyelination; myelin debris; remyelination Nogo-A; Nogo receptor; multiple sclerosis; axonal dystrophy; inflammatory demyelination; myelin debris; remyelination
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Kim, M.J.; Kang, J.H.; Theotokis, P.; Grigoriadis, N.; Petratos, S. Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS? Cells 2019, 8, 1.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top